Published in Immunology on July 04, 2007
Post-production protein stability: trouble beyond the cell factory. Microb Cell Fact (2011) 0.84
Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol (2001) 6.20
Dendritic cell immunotherapy: mapping the way. Nat Med (2004) 4.28
Danger signals: SOS to the immune system. Curr Opin Immunol (2001) 3.91
Endogenous ligands of Toll-like receptors. J Leukoc Biol (2004) 3.53
Crystal structure of the nucleotide exchange factor GrpE bound to the ATPase domain of the molecular chaperone DnaK. Science (1997) 3.31
Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer Res (2001) 2.54
Protein transduction: unrestricted delivery into all cells? Trends Cell Biol (2000) 2.37
In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol Sci (2000) 2.35
Targeting p53 as a general tumor antigen. Proc Natl Acad Sci U S A (1995) 2.09
New fusion protein systems designed to give soluble expression in Escherichia coli. Biotechnol Bioeng (1999) 2.04
Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol (1995) 1.85
The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann N Y Acad Sci (2000) 1.71
Purification of correctly oxidized MHC class I heavy-chain molecules under denaturing conditions: a novel strategy exploiting disulfide assisted protein folding. Protein Sci (2003) 1.16
Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc Natl Acad Sci U S A (1996) 1.14
Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses. Clin Exp Immunol (1999) 1.11
Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity. J Immunol (2002) 1.11
Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer. Cancer Res (2002) 1.09
p53: a potential target antigen for immunotherapy of cancer. Ann N Y Acad Sci (2000) 1.08
Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol Immunother (2007) 1.05
Gene-modified dendritic cells for use in tumor vaccines. Hum Gene Ther (2000) 1.04
Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother (2004) 1.02
Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity. Eur J Immunol (2001) 1.01
Heat shock proteins as vaccine adjuvants in infections and cancer. Drug Discov Today (2006) 1.01
GrpE, a nucleotide exchange factor for DnaK. Cell Stress Chaperones (2003) 1.00
Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur J Immunol (1995) 0.95
Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma. Eur J Immunol (2003) 0.93
Identification and design of p53-derived HLA-A2-binding peptides with increased CTL immunogenicity. Scand J Immunol (2001) 0.90
Peptide-loaded dendritic cells prime and activate MHC-class I-restricted T cells more efficiently than protein-loaded cross-presenting DC. Cell Immunol (2003) 0.88
Identification of p53 peptides recognized by CD8(+) T lymphocytes from patients with bladder cancer. Hum Immunol (2001) 0.86
Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin Cancer Res (2002) 0.86
Refolding and structural characterization of the human p53 tumor suppressor protein. Biophys Chem (2002) 0.86
Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein. Scand J Immunol (2000) 0.85
Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients. Cancer Gene Ther (2003) 0.84
Tolerogenic dendritic cells pulsed with enterobacterial extract suppress development of colitis in the severe combined immunodeficiency transfer model. Immunology (2007) 0.83
The mode of presentation and route of administration are critical for the induction of immune responses to p53 and antitumor immunity. Vaccine (1998) 0.82
High efficiency protein transduction of quiescent and proliferating primary hematopoietic cells. J Biochem Biophys Methods (2003) 0.77
Development of vaccines against self-antigens: the p53 paradigm. Curr Opin Drug Discov Devel (2003) 0.76
The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. Science (1987) 5.32
Isolation and characterization of antigen-Ia complexes involved in T cell recognition. Cell (1986) 4.71
Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells. Nature (1987) 3.63
Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis. Proc Natl Acad Sci U S A (1989) 2.73
Immunological self, nonself discrimination. Science (1987) 2.59
Interaction between a "processed" ovalbumin peptide and Ia molecules. Proc Natl Acad Sci U S A (1986) 2.42
Age of second-language acquisition and perception of speech in noise. J Speech Lang Hear Res (1997) 2.00
Structural analysis of peptides capable of binding to more than one Ia antigen. J Immunol (1989) 1.85
Establishment of a quantitative ELISA capable of determining peptide - MHC class I interaction. Tissue Antigens (2002) 1.68
Capacity of intact proteins to bind to MHC class II molecules. J Immunol (1989) 1.63
I-Ad-binding peptides derived from unrelated protein antigens share a common structural motif. J Immunol (1988) 1.61
SARS CTL vaccine candidates; HLA supertype-, genome-wide scanning and biochemical validation. Tissue Antigens (2004) 1.52
Interaction of an immunodominant epitope with Ia molecules in T-cell activation. Proc Natl Acad Sci U S A (1988) 1.51
Treatment of atopic dermatitis with mycophenolate mofetil. Br J Dermatol (2000) 1.39
Using statistical decision theory to predict speech intelligibility. I. Model structure. J Acoust Soc Am (2001) 1.31
Peptide binding specificity of major histocompatibility complex class I resolved into an array of apparently independent subspecificities: quantitation by peptide libraries and improved prediction of binding. Eur J Immunol (1996) 1.30
Release from masking caused by envelope fluctuations. J Acoust Soc Am (1985) 1.29
Complete protection against lethal Toxoplasma gondii infection in mice immunized with a plasmid encoding the SAG1 gene. Infect Immun (1999) 1.26
MHC molecules protect T cell epitopes against proteolytic destruction. J Immunol (1992) 1.25
A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Proc Natl Acad Sci U S A (1996) 1.24
Complete dissection of the Hb(64-76) determinant using T helper 1, T helper 2 clones, and T cell hybridomas. J Immunol (1992) 1.24
Quantitative predictions of peptide binding to MHC class I molecules using specificity matrices and anchor-stratified calibrations. Tissue Antigens (2001) 1.23
Gut-homing CD4+ T cell receptor alpha beta+ T cells in the pathogenesis of murine inflammatory bowel disease. Eur J Immunol (1994) 1.21
Relative contribution of "determinant selection" and "holes in the T-cell repertoire" to T-cell responses. Proc Natl Acad Sci U S A (1989) 1.20
T cell responses affected by aminopeptidase N (CD13)-mediated trimming of major histocompatibility complex class II-bound peptides. J Exp Med (1996) 1.19
Efficient assembly of recombinant major histocompatibility complex class I molecules with preformed disulfide bonds. Eur J Immunol (2001) 1.19
Frequency selectivity in normally-hearing and hearing-impaired observers. J Speech Hear Res (1980) 1.19
Predicting binding affinities of protein ligands from three-dimensional models: application to peptide binding to class I major histocompatibility proteins. J Med Chem (1999) 1.14
Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc Natl Acad Sci U S A (1996) 1.14
Oligopeptide antigens of the angiotensin lineage compete for presentation by paraformaldehyde-treated accessory cells to T cells. J Immunol (1986) 1.14
Light and electron microscopic studies of the paracortical post-capillary high-endothelial venules. Z Zellforsch Mikrosk Anat (1971) 1.13
The role of up-regulated serine proteases and matrix metalloproteinases in the pathogenesis of a murine model of colitis. Am J Pathol (2000) 1.12
Temporal integration in normal hearing, cochlear impairment, and impairment simulated by masking. J Acoust Soc Am (1988) 1.10
Effective attenuation of signals in noise under focused attention. J Acoust Soc Am (1991) 1.10
Structural requirements for the interaction between peptide antigens and I-Ed molecules. J Immunol (1989) 1.09
The interaction of beta 2-microglobulin (beta 2m) with mouse class I major histocompatibility antigens and its ability to support peptide binding. A comparison of human and mouse beta 2m. Eur J Immunol (1995) 1.07
Role of the T cell receptor ligand affinity in T cell activation by bacterial superantigens. J Biol Chem (2001) 1.05
Identifying cytotoxic T cell epitopes from genomic and proteomic information: "The human MHC project.". Rev Immunogenet (2000) 1.05
Comodulation masking release for three types of modulator as a function of modulation rate. Hear Res (1989) 1.03
Selective engraftment of memory CD4+ T cells with an unusual recirculation pattern and a diverse T cell receptor-V beta repertoire into scid mice. Eur J Immunol (1993) 1.02
Temporal gap detection in sensorineural and simulated hearing impairments. J Speech Hear Res (1984) 1.01
The T-cell accessory molecule CD4 recognizes a monomorphic determinant on isolated Ia. Proc Natl Acad Sci U S A (1988) 1.01
MHC-I-restricted epitopes conserved among variola and other related orthopoxviruses are recognized by T cells 30 years after vaccination. Arch Virol (2008) 0.98
Decision rules in detection of simple and complex tones. J Acoust Soc Am (1986) 0.98
Temporal integration of loudness as a function of level. J Acoust Soc Am (1996) 0.98
The P9 pocket of HLA-DQ2 (non-Aspbeta57) has no particular preference for negatively charged anchor residues found in other type 1 diabetes-predisposing non-Aspbeta57 MHC class II molecules. Int Immunol (1998) 0.97
Early detection of cancer in the general population: a blinded case-control study of p53 autoantibodies in colorectal cancer. Br J Cancer (2012) 0.96
MHC class I ligation of human T cells activates the ZAP70 and p56lck tyrosine kinases, leads to an alternative phenotype of the TCR/CD3 zeta-chain, and induces apoptosis. J Immunol (1997) 0.96
pH dependence of MHC class I-restricted peptide presentation. J Immunol (1996) 0.96
pH dependence of the interaction between immunogenic peptides and MHC class II molecules. Evidence for an acidic intracellular compartment being the organelle of interaction. J Immunol (1992) 0.95
A quantitative assay to measure the interaction between immunogenic peptides and purified class I major histocompatibility complex molecules. Eur J Immunol (1994) 0.94
Selective reconstitution of T lymphocyte subsets in scid mice. Immunol Rev (1991) 0.94
Experimental methods and modeling techniques for description of cell population heterogeneity. Biotechnol Adv (2011) 0.93
Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4. Cancer Lett (2005) 0.93
Direct binding of autoimmune disease related T cell epitopes to purified Lewis rat MHC class II molecules. Int Immunol (1994) 0.93
The interaction between beta 2-microglobulin (beta 2m) and purified class-I major histocompatibility (MHC) antigen. Scand J Immunol (1994) 0.93
MHC class II-derived peptides can bind to class II molecules, including self molecules, and prevent antigen presentation. J Exp Med (1990) 0.93
Intensity perception. XIV. Intensity discrimination in listeners with sensorineural hearing loss. J Acoust Soc Am (1993) 0.92
CD3+ T cells in severe combined immunodeficiency (scid) mice. II. Transplantation of dm2 lymphoid cells into semi-allogeneic scid mice. Eur J Immunol (1991) 0.92
Strategies to work with HLA data in human populations for histocompatibility, clinical transplantation, epidemiology and population genetics: HLA-NET methodological recommendations. Int J Immunogenet (2012) 0.92
Binding of peptides to HLA-DQ molecules: peptide binding properties of the disease-associated HLA-DQ(alpha 1*0501, beta 1*0201) molecule. Int Immunol (1994) 0.91
Quantitative studies on the decay of lymphoid cells during the development of casein-induced murine amyloidosis. Acta Pathol Microbiol Scand A (1972) 0.91
Level discrimination of sinusoids as a function of duration and level for fixed-level, roving-level, and across-frequency conditions. J Acoust Soc Am (2000) 0.91
Chloroquine inhibits accessory cell presentation of soluble natural and synthetic protein antigens. Acta Pathol Microbiol Immunol Scand C (1984) 0.91
Identification and design of p53-derived HLA-A2-binding peptides with increased CTL immunogenicity. Scand J Immunol (2001) 0.90
Immunobiological effects of glucosamine in vitro. Scand J Immunol (2003) 0.90
Phenotypic and functional markers for 1alpha,25-dihydroxyvitamin D(3)-modified regulatory dendritic cells. Clin Exp Immunol (2009) 0.90
Tumor-associated antigens identified by mRNA expression profiling induce protective anti-tumor immunity. Eur J Immunol (2001) 0.90
Cytotoxic reactivity of gut lamina propria CD4+ alpha beta T cells in SCID mice with colitis. Eur J Immunol (1996) 0.89
Self-peptides with intermediate capacity to bind and stabilize MHC class I molecules may be immunogenic. Scand J Immunol (2003) 0.89
Increased intracellular Th1 cytokines in scid mice with inflammatory bowel disease. Eur J Immunol (1998) 0.89
Activation of Stat-3 is involved in the induction of apoptosis after ligation of major histocompatibility complex class I molecules on human Jurkat T cells. Blood (1998) 0.89
Histochemistry and development of the human eyelids. II. A cytochemical and electron microscopical study. Acta Ophthalmol (Copenh) (1967) 0.89
In vivo infiltration of mononuclear cells in squamous cell carcinoma of the head and neck correlates with the ability to expand tumour-infiltrating T cells in vitro and with the expression of MHC class I antigens on tumour cells. Cancer Immunol Immunother (1994) 0.88
Improved humoral and cellular immune responses against the gp120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted into the hepatitis B surface antigen. Scand J Immunol (1998) 0.88
Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate. Scand J Immunol (2009) 0.88
Reversibility of alcohol-induced immune depression. Br J Addict (1992) 0.87
Characterization of monocyte-derived dendritic cells maturated with IFN-alpha. Scand J Immunol (2006) 0.87
Preformed purified peptide/major histocompatibility class I complexes are potent stimulators of class I-restricted T cell hybridomas. Eur J Immunol (1994) 0.87
Effect of conformational propensity of peptide antigens in their interaction with MHC class II molecules. Failure to document the importance of regular secondary structures. J Immunol (1989) 0.87
High-affinity human leucocyte antigen class I binding variola-derived peptides induce CD4+ T cell responses more than 30 years post-vaccinia virus vaccination. Clin Exp Immunol (2009) 0.87
A gut-homing, oligoclonal CD4+ T cell population in severe-combined immunodeficient mice expressing a rearranged, transgenic class I-restricted alpha beta T cell receptor. Eur J Immunol (1995) 0.87
Ligation of MHC class I molecules on peripheral blood T lymphocytes induces new phenotypes and functions. J Immunol (1996) 0.86
MHC class I signaling in T cells leads to tyrosine kinase activity and PLC-gamma 1 phosphorylation. J Immunol (1995) 0.86
Toward a clinical procedure for narrowband gap detection I: a psychophysical procedure. Audiology (2000) 0.86
Binding of peptides from the N-terminal region of alpha-gliadin to the celiac disease-associated HLA-DQ2 molecule assessed in biochemical and T cell assays. Clin Immunol Immunopathol (1996) 0.86
CD3+ T-cells in severe combined immunodeficiency (scid) mice. III. Transferred congenic, selfreactive CD4+ T cell clones rescue IgM-producing, scid-derived B cells. Int Immunol (1991) 0.86
Phenotypic and functional characterization of clinical grade dendritic cells generated from patients with advanced breast cancer for therapeutic vaccination. Scand J Immunol (2005) 0.85
Shared fine specificity between T-cell receptors and an antibody recognizing a peptide/major histocompatibility class I complex. Proc Natl Acad Sci U S A (1996) 0.85